CD8 (cluster of differentiation 8)

Targeted modulation of TSL via cytokine supplementation, immune checkpoint blockade, adoptive transfer, or niche interference is under investigation, with encouraging results in preclinical and early translational studies. This review outlines the molecular regulation and functional diversity of stem-like CD4+ and CD8+ T cells, evaluates their disease-specific roles, and discusses strategies to harness or inhibit these populations for precision immunotherapy.

Plasma proteomics revealed shared mediators including interleukin-6 and EN-RAGE across anatomical sites and ages. Together, our findings delineate anatomical-specific and age-specific immune programs in sepsis, highlighting candidate targets for precision immunotherapy.

We report a case illustrating how the investigation of a proliferation of double-negative αβ T lymphocytes led to the diagnosis of cholangiocarcinoma. Although a direct link between the two cannot be proven, we hypothesize that tumor antigenic stimulation selected a T lymphocyte clone.

Here, we synthesize insights from these approaches to define diverse CD8+ T-cell subsets and exhaustion trajectories, as well as the origins, phenotypic diversity, and functional states of other immune cells including tumor-associated macrophages, dendritic cells, natural killer cells and cancer-associated fibroblasts. Together, these findings highlight the transformative potential of single-cell technologies to unravel TME complexity, identify biomarkers of therapeutic response, and guide precision immunotherapy in RCC.

lncRNA NEAT1 serves as a modulator of the antitumor response of CD8+T cells in the bladder tumor microenvironment and may represent a therapeutic target for reversing T-cell exhaustion.

Additionally, the expression of M2 macrophage polarization-related proteins CD163 and CD206 was downregulated (p < 0.05). Our findings suggest that the combination of IP6 and INS alleviates CRC metastasis by downregulating the PI3K/AKT pathway and influencing macrophage polarization, with the most significant inhibitory effect observed at an IP6-to-INS ratio of 1 : 3.

Although a RORγ agonist (LYC-55716) has been under clinical evaluation, the precise effects of RORγ agonists on immune cells within tumor environments remain unclear...Moreover, the addition of Th17-derived cytokines to MC38 cells stimulated the release of CXCL10, a chemokine crucial for immune cell recruitment. These results offer valuable insights into the immunomodulatory and therapeutic potential of RORγ agonists in cancer immunotherapy, highlighting their role in enhancing immune cell infiltration and activity within tumors.

Animal experiments indicate that Ctsa knockdown effectively enhances ICB efficacy on PDAC. Our study uncovers a VAT-EV CTSA-pseudouridine-mast cell axis connecting obesity and cancer, which holds promise for developing new therapeutic strategies for obesity-related cancers.

FACS analysis showed loss of co-stimulatory CD80, an immune synapse component, following B3gat1 knockdown. These results suggest that loss of HNK-1 expression contributes to tumor immune escape through loss of immune recognition and attack via downregulation of tumor cell surface co-stimulatory molecules, leading to reduced CD8+ T-cell activation and immune synapse formation, and increased T-cell apoptosis.

The NK cell-related gene signature serves as a robust prognostic biomarker and predictor of immunotherapeutic efficacy in BC. These findings provide new insights into BC biology and facilitate personalized immunotherapy strategies.

The reduction of PD-1 expression on CD4⁺ T cells and decreased myeloid-derived suppressor cells were also associated with better outcomes. These findings suggest PBF-1129 is safe and modulates the systemic immune parameters, warranting further evaluation in combination with immune checkpoint blockade.

RNA sequencing analysis demonstrated that NP3 synergistically promoted tumor regression by concurrently inducing pro-apoptotic signaling and immune responses. In conclusion, this study presents an innovative therapeutic strategy combining targeted chemotherapy delivery with robust antitumor metalloimmunotherapy, offering a promising therapeutic approach for OS.